TVM Capital has reorganised its life science investment practice. In the future, the firm will operate two dedicated teams with differentiated investment concepts to invest in pharmaceutical, biopharmaceutical, medical technologies (medtech) and healthcare services companies. The divisions will be called Healthcare Private Equity and Life Science Venture Capital.
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap